Profile data is unavailable for this security.

About the company

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States. Its Diagnostic Products include a range of diagnostic systems and tests. Its Nutritional Products include a range of pediatric and adult nutritional products. Its Company's Vascular Products include a range of coronary, endovascular, vessel closure and structural heart devices for the treatment of vascular disease. The Company, through St. Jude Medical, Inc., also offers products, such as rhythm management products, electrophysiology products, heart failure related products, vascular products, structural heart products and neuromodulation products.

  • Revenue in USD (TTM)28.45bn
  • Net income in USD1.85bn
  • Incorporated1900
  • Employees99.00k
  • Location
    Abbott Laboratories100 Abbott Park RdNORTH CHICAGO 60064-3500United StatesUSA
  • Phone+1 (847) 937-6100
  • Websitehttp://www.abbott.com
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Allergan plc16.04bn-4.50bn59.56bn17.80k--0.823320.893.71-13.47-6.2348.07213.360.13432.426.19901,118.00-3.55-3.28-3.81-3.5686.0379.93-26.43-26.440.9362-0.10730.2686--9.4021.93-457.69--45.77--
Celgene Corporation13.58bn4.12bn62.23bn7.47k16.5212.1513.524.585.203.5617.137.060.42850.92447.531,818,535.0013.0110.5514.3111.8196.4495.7130.3623.632.36--0.79670.0015.8018.75110.5323.6511.71--
Biogen Inc12.59bn4.14bn74.90bn7.30k18.175.3414.965.9519.5413.9959.4766.450.53271.875.831,725,247.0018.0518.7020.7321.9086.5787.5233.8831.262.9518.460.29710.007.2117.340.267421.8949.69--
Bristol-Myers Squibb Co21.04bn3.82bn92.56bn23.70k24.397.2419.874.402.320.55212.817.830.63744.764.98887,763.7011.638.4716.1111.6770.3974.0918.2516.421.39--0.373785.446.943.35-12.4314.7814.002.63
Eli Lilly And Co23.34bn3.04bn97.22bn40.66k31.046.6920.954.162.891.0522.2013.380.56951.465.48574,172.907.417.5110.1510.2372.9575.0913.0213.051.0188.640.44577.167.770.2359-37.54-16.000.61681.20
Gilead Sciences, Inc.24.69bn8.96bn100.38bn10.00k11.354.879.724.076.802.6018.7615.840.40123.746.322,469,000.0014.5926.8517.3333.3482.1284.6036.3545.392.7511.260.584512.47-14.0921.89-25.0431.328.24--
Abbott Laboratories28.45bn1.85bn110.10bn99.00k59.473.5122.243.871.060.269516.2417.910.40123.165.77287,323.202.613.682.944.5456.6155.356.518.471.243.640.409279.6831.357.5370.5650.22-8.76-12.01
Amgen, Inc.22.94bn8.39bn128.32bn20.80k16.788.2712.465.5911.563.0431.5623.440.30791.386.671,102,837.0011.279.3913.1110.7182.4980.9636.5931.043.6028.720.694738.42-0.61765.764.6213.21-0.736526.15
AbbVie Inc29.61bn9.96bn151.40bn29.00k15.3442.6113.,021,103.0014.7911.5318.3014.8875.7877.2733.7122.441.106.880.91365.1510.068.9549.9710.999.70--
Data as of Jul 17 2018. Currency figures normalised to Abbott Laboratories's reporting currency: US Dollar USD

Institutional shareholders

31.91%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 31 Mar 2018131.35m7.49%
Capital Research & Management Co. (Global Investors)as of 31 Mar 2018113.10m6.45%
BlackRock Fund Advisorsas of 31 Mar 201879.12m4.51%
SSgA Funds Management, Inc.as of 31 Mar 201868.63m3.92%
Wellington Management Co. LLPas of 31 Mar 201843.80m2.50%
Massachusetts Financial Services Co.as of 31 Mar 201839.81m2.27%
Northern Trust Investments, Inc.as of 31 Mar 201826.06m1.49%
T. Rowe Price Associates, Inc.as of 31 Mar 201819.60m1.12%
Geode Capital Management LLCas of 31 Mar 201819.21m1.10%
Norges Bank Investment Managementas of 31 Dec 201718.69m1.07%
More ▼
Data from 31 Dec 2017 - 31 Mar 2018Source: FactSet Research Systems Inc.
© Thomson Reuters Click for restrictions
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.